MASLD in type 2 diabetes: steatosis-fibrosis burden and metabolic determinants in a real-world cohort.
Abdominal adiposity identifies steatosis risk in a graded manner but does not discriminate fibrosis, supporting adiposity- and sex-informed hepatic phenotyping in patients with T2DM.